Dossier
DCVax
Coverage of DCVax in the Nexus archive.
- STAT+: 931 days. The drug approval scandal hiding in plain sight
Northwest Biotherapeutics submitted a marketing application for its brain cancer treatment DCVax to U.K. regulators in late December 2023 under an expedited pathway expecting a 150-day review. Over 931 days later, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has not approved the drug and refuses to comment, deferring updates to the company.